Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

info@bullrun.co.in

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

  1. Home
  2. /
  3. Sectors
  4. /
  5. Civil Construction
  6. /
  7. Teva Pharmaceutical Industries Ltd
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsBalance SheetProfit & LossCash Flow
HomeStocksCivil ConstructionTeva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd Stock Price Today (NSE: IL&FSTRANS)

Teva Pharmaceutical Industries Ltd

IL&FSTRANSCivil Construction
₹1.84₹0.10 (4.93%)↓
As on 30 Mar 2026, 12:03 pm ISTMarket Closed

Fundamental Score

...

Teva Pharmaceutical Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Teva Pharmaceutical Industries Ltd share price today is ₹1.84, down 4.93% on NSE/BSE as of 30 March 2026. Teva Pharmaceutical Industries Ltd (IL&FSTRANS) is a Small-cap company in the Civil Construction sector with a market capitalisation of ₹93.05 (Cr). The 52-week high for IL&FSTRANS share price is ₹4.40 and the 52-week low is ₹1.93.

Teva Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
-4.93%

Returns & Performance

ROE

N/A
Poor

ROCE

-18.13%
Poor

OPM (5Y)

2.29%

Div Yield

0.00%

Teva Pharmaceutical Industries Ltd Valuation Check

P/E Ratio

N/A
Poor

Industry P/E

18.93x
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Market Cap

93.05 (Cr)

Growth Engine

Poor

Profit Growth (Q)

-1100.85%
Poor

Sales Growth (Q)

7.66%
Poor

Sales Growth (5Y)

-51.00%

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Balance Sheet Health

Debt to Equity

N/A
Poor

Int. Coverage

-10.02x

Free Cash Flow (5Y)

847.07 (Cr)

Shareholding

Excellent

Promoter

73.22%
Poor

FII

0.00%
Poor

DII

0.42%
Poor

Pledged

98.23%

Institutional Deep-Dive

Bull Run Research Hub

Teva Pharmaceutical Share Price: A Financial Analysis

A key trend shaping the civil construction industry is the increasing emphasis on sustainable and technologically advanced building practices, demanding companies possess both financial strength and innovative capabilities. This analysis delves into the Teva Pharmaceutical share price, currently at ₹2.67, to understand its financial health within this evolving landscape. Examining the available metrics, particularly the absence of a Price-to-Earnings (PE) ratio and a Return on Capital Employed (ROCE) of -18.13%, offers insights into the company's current position.

The lack of a PE ratio suggests the company might not be currently profitable, preventing a standard valuation comparison. More concerning is the negative ROCE of -18.13%. This indicates that Teva Pharmaceutical is not effectively generating profit from its invested capital. This significantly impacts the company's moat, or competitive advantage, because it reduces its ability to reinvest in growth, innovation, or defend market share. A sustained negative ROCE can signal underlying operational inefficiencies or financial distress.

When considering sector peers, it is useful to see how Teva's management stacks up. For example, how does the leadership quality of Teva Pharmaceutical compare to that of MBL Infrastructure Ltd? A comparative analysis of management experience, capital allocation decisions, and strategic vision could reveal differentiating factors that influence investor confidence and long-term performance.

In summary, a deeper dive is warranted to investigate the reasons behind the negative ROCE and the lack of profitability impacting the PE ratio. Understanding the strategic initiatives implemented to address these issues is crucial for assessing the long-term prospects of Teva Pharmaceutical. This analysis is part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a comprehensive overview of the company's financial standing. Note that this is an observational analysis, and is not intended to provide financial advice.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Teva Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of IL&FSTRANS across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Strong Cash Generation (₹847.07 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (73.22%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Risk Factors

8 factors identified

Suboptimal ROCE (-18.13%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (2.29%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-1100.85%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Growth History (-51.00% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-10.02x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.42%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

High Share Pledging Risk (98.23%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Teva Pharmaceutical Industries Ltd Financial Statements

Comprehensive financial data for Teva Pharmaceutical Industries Ltd including income statement, balance sheet and cash flow

About IL&FSTRANS (Teva Pharmaceutical Industries Ltd)

Teva Pharmaceutical Industries Ltd is a global pharmaceutical titan, renowned for its extensive portfolio of generic and specialty medicines. With a presence spanning continents, T...eva operates a vast network of manufacturing facilities and research and development centers dedicated to producing affordable and accessible healthcare solutions. From complex generics that challenge the status quo to innovative branded therapies addressing critical medical needs, Teva strives to improve patient outcomes worldwide. Their commitment to quality and compliance is paramount, ensuring that every product meets the highest standards of safety and efficacy. This global footprint demands a strong operational backbone, including robust supply chains and logistical networks that allow for the timely distribution of medications to healthcare providers and patients. IL&FSTRANS, a key player in civil construction, focuses on building and maintaining vital transport networks. Imagine a tapestry of asphalt stretching across vast landscapes, connecting bustling urban centers and remote rural communities – that is the work of IL&FSTRANS. They engineer and oversee the development of highways that hum with the passage of commerce, soaring flyovers that untangle congested city streets, and sturdy bridges that span formidable rivers. Beyond concrete and steel, they contribute to the very arteries of movement that enable economic growth and social connection. The company's commitment extends to the ongoing care of these vital routes, providing essential maintenance and toll collection services to ensure their long-term viability and efficiency. IL&FSTRANS are not just builders; they are caretakers of infrastructure, responsible for keeping transportation flowing smoothly. From the initial blueprint to the final coat of paint, they manage every aspect of these intricate projects, ensuring that each structure meets stringent safety standards and environmental regulations. Their expertise extends beyond traditional roadwork to include modern transit systems like metro rail projects and efficient city bus networks. With a commitment to sustainable practices, they incorporate innovative design and materials to minimize environmental impact. Ultimately, their work empowers the efficient movement of people and goods, fostering progress and connectivity across communities and regions.

Company Details

Symbol:IL&FSTRANS
Industry:Civil Construction
Sector:Civil Construction
Website:https://www.itnlindia.com

Key Leadership

Mr. Milind Ramesh Gandhi
CFO, VP of Finance/Accounts
Mr. Krishna D. Ghag
VP, Compliance Officer & Company Secretary
Mr. Manish Kumar Agarwal B.E.
Senior Vice President

Corporate Events

Recent
Ex-Dividend Date
2016-07-29

Latest News

Russia to Demonstrate HAL-branded SJ-100 and Il-114-300 Regional Aircraft at Wings India 2026 in Hyderabad - Defence.in
Defence.in• 12/31/2025
Park Geon-il's Resolute Leadership Shines in 'The First Man' - 조선일보
조선일보• 1/2/2026
Cherries, Melinda and Vip accelerate 'late mountain' production - Il Sole 24 ORE
Il Sole 24 ORE• 1/2/2026

IL&FSTRANS Share Price: Frequently Asked Questions

What is the current share price of Teva Pharmaceutical Industries Ltd (IL&FSTRANS)?

As of 30 Mar 2026, 12:03 pm IST, Teva Pharmaceutical Industries Ltd share price is ₹1.84. The IL&FSTRANS stock has a market capitalisation of ₹93.05 (Cr) on NSE/BSE.

Is IL&FSTRANS share price Overvalued or Undervalued?

IL&FSTRANS share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 18.93x. Based on this relative valuation, the Teva Pharmaceutical Industries Ltd stock appears to be Fairly Valued against its sector peers.

What is the 52-week high and low of IL&FSTRANS share price?

The 52-week high of IL&FSTRANS share price is ₹4.40 and the 52-week low is ₹1.93. These values are updated daily from NSE/BSE price data.

What factors affect the Teva Pharmaceutical Industries Ltd share price?

Key factors influencing IL&FSTRANS share price include quarterly earnings growth (Sales Growth: 7.66%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Teva Pharmaceutical Industries Ltd a good stock for long-term investment?

Teva Pharmaceutical Industries Ltd shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in IL&FSTRANS shares.

How does Teva Pharmaceutical Industries Ltd compare with its industry peers?

Teva Pharmaceutical Industries Ltd competes with major peers in the Civil Construction. Investors should compare IL&FSTRANS share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.

What is the P/E ratio of IL&FSTRANS and what does it mean?

IL&FSTRANS share price has a P/E ratio of N/Ax compared to the industry average of 18.93x. Investors pay ₹N/A for every ₹1 of annual earnings.

How is IL&FSTRANS performing according to Bull Run's analysis?

IL&FSTRANS has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does IL&FSTRANS belong to?

IL&FSTRANS operates in the Civil Construction industry. This classification helps understand the competitive landscape and sector-specific trends affecting Teva Pharmaceutical Industries Ltd share price.

What is Return on Equity (ROE) and why is it important for IL&FSTRANS?

IL&FSTRANS has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Teva Pharmaceutical Industries Ltd generates profits from shareholders capital.

How is IL&FSTRANS debt-to-equity ratio and what does it indicate?

IL&FSTRANS has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.

What is IL&FSTRANS dividend yield and is it a good dividend stock?

IL&FSTRANS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Teva Pharmaceutical Industries Ltd shares.

How has IL&FSTRANS share price grown over the past 5 years?

IL&FSTRANS has achieved 5-year growth rates of: Sales Growth -51.00%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in IL&FSTRANS and why does it matter?

Promoters hold 73.22% of IL&FSTRANS shares, with 98.23% pledged. High promoter holding often indicates strong management confidence in Teva Pharmaceutical Industries Ltd.

What is IL&FSTRANS market capitalisation category?

IL&FSTRANS has a market capitalisation of ₹93 crores, placing it in the Small-cap category.

How volatile is IL&FSTRANS stock?

IL&FSTRANS has a beta of N/A. A beta > 1 suggests the Teva Pharmaceutical Industries Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is IL&FSTRANS operating profit margin trend?

IL&FSTRANS has a 5-year average Operating Profit Margin (OPM) of 2.29%, indicating the company's operational efficiency.

How is IL&FSTRANS quarterly performance?

Recent quarterly performance shows Teva Pharmaceutical Industries Ltd YoY Sales Growth of 7.66% and YoY Profit Growth of -1100.85%.

What is the institutional holding pattern in IL&FSTRANS?

IL&FSTRANS has FII holding of 0.00% and DII holding of 0.42%. Significant institutional holding often suggests professional confidence in the Teva Pharmaceutical Industries Ltd stock.

HomeScreenerBattleWatchlist

Frequently Asked Questions about Teva Pharmaceutical Industries Ltd

What is the current share price of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd (IL&FSTRANS) trades at ₹1.84 on NSE and BSE. Market cap ₹93.05 (Cr). Educational data only.

What is the P/E ratio of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has a P/E of N/Ax vs industry average 18.93x.

What is the Bull Run score for Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.

Does Teva Pharmaceutical Industries Ltd pay dividends?

Teva Pharmaceutical Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has debt-to-equity of N/A.

Is Teva Pharmaceutical Industries Ltd a good investment?

Bull Run gives Teva Pharmaceutical Industries Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.